Maribavir vs. Valganciclovir for CMV Viremia in Recipients of Hematopoietic Cell Transplantation

Although maribavir failed to achieve noninferiority to valganciclovir in clearance of CMV viremia after 8 weeks, the two agents were equivalent in maintaining subsequent clearance.

Preemptive treatment of cytomegalovirus (CMV) is an effective strategy for preventing tissue-invasive disease in patients receiving hematopoietic cell transplants (HCTs). However, current therapy is often complicated by toxicity such as myelosuppression with valganciclovir and renal dysfunction with foscarnet and cidofovir. Maribavir, an orally available agent with a unique mechanism of action (inhibition of CMV-specific U97 protein kinase), has been approved for post-transplantation treatment of CMV infection.

In the AURORA trial — a phase 3, double-blind study conducted at 97 centers around the world between April and July 2022 — 553 patients with allogeneic HCTs and their first episode of CMV viremia without tissue invasion were randomize…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Maribavir vs. Valganciclovir for CMV Viremia in Recipients of Hematopoietic Cell Transplantation

Topics

Reviewing Author